Infant Bacterial Therapeutics AB (publ), Interim report January 1-June 30, 2023
Message from the CEO Our Phase-III study, the largest of its kind ever conducted, is progressing...
August 25, 2023
New number of shares and votes in IBT
The number of shares and votes in Infant Bacterial Therapeutics AB (publ) has changed due to the...
July 31, 2023
IBT announces outcome of its rights issue
To access the press release, please read the following disclaimer here.
July 4, 2023
Additional Infant Bacterial Therapeutics product receives FDA orphan drug designation
The FDA has granted orphan drug designation for IBT’s product IBP-1016 for...
July 3, 2023
The futility analysis for IBT’s Connection Study positive
“IBT announced earlier today that the Data Monitoring Committee (DMC) has performed the planned...
June 21, 2023
IBT continues to recruit prematurely born infants to The Connection Study following a planned safety analysis.
In accordance with the study protocol, the independent Data Monitoring Committee (DMC) has...
June 21, 2023
New patent for Infant Bacterial Therapeutics has been approved in Europe
Infant Bacterial Therapeutics AB (IBT) announces today that the European Patent Office has approved...
June 15, 2023
IBT publishes prospectus
To access the press release and prospectus, please read the following disclaimer here.
June 13, 2023
Extraordinary General Meeting of Infant Bacterial Therapeutics
At the Extraordinary General Meeting of Infant Bacterial Therapeutics AB (publ) on June 9, 2023, it...
June 9, 2023
Notice of Extraordinary General Meeting of Infant Bacterial Therapeutics
Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in...
May 16, 2023
Infant Bacterial Therapeutics AB (publ), Interim report January 1-March 31, 2023
Message from the CEO Significant advancements have been made in the development of...
May 8, 2023
Annual General Meeting of Infant Bacterial Therapeutics
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 8, 2023, among...
May 8, 2023
Notice of Annual General Meeting of Infant Bacterial Therapeutics
Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in...
April 3, 2023
Infant Bacterial Therapeutics publishes Annual Report for 2022
The report is available on IBT´s website, ibtherapeutics.com under the section "Investors &...
March 23, 2023
Infant Bacterial Therapeutics’ (IBT) opening of a final infant cohort will accelerate patient recruitment
IBT is pleased to announce today's opening of the additional cohort, having included 1,400...
March 22, 2023
Infant Bacterial Therapeutics AB (publ) Interim report January 1- December 31, 2022
Message from the CEO The speed of recruitment of preterm infants into our large phase 3 study...
February 10, 2023
Infant Bacterial Therapeutics publishes Annual Report for 2021 in XHTML format
On March 31 2022 IBT published the 2021 annual report in the format of a PDF file. Today, IBT...
January 27, 2023
Infant Bacterial Therapeutics’ (IBT) publishes clinical findings in the British Journal of Gastroenterology on the convincing association of clinical events to the feeding primary endpoint of the ‘Connection Study’
The ‘Connection Study’ on the pharmaceutical grade probiotic IBP-9414 has two independent...
January 24, 2023
IBT secures platform for pharma grade probiotic to prevent antibiotic resistant hospital acquired infections
Building upon the company's unique expertise in developing pharma grade probiotics, Infant...
January 12, 2023
Infant Bacterial Therapeutics AB (publ) (IBT), Interim Management Statement, July 1 – September 30, 2022
Message from the CEO Our IBP-9414 clinical phase III development project is progressing well, and...
November 10, 2022
Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomination Committee for the Annual General Meeting 2023
The 2022 Annual General Meeting resolved that the Chairman of the Board shall convene the three...
November 4, 2022
Article based on Infant Bacterial Therapeutics’ (IBT) Connection Study published in the British Journal of Gastroenterology demonstrates that one day shift in Sustained Feeding Tolerance (SFT) correlates to clinically meaningful outcomes.
The two independent primary endpoints of the ‘Connection Study’ are the incidence of NEC and...
November 1, 2022
FDA approves Infant Bacterial Therapeutics’ request for a new orphan drug designation
Building upon Infant Bacterial Therapeutics AB’s (IBT) unique expertise in developing treatment...
September 23, 2022
Infant Bacterial Therapeutics AB (publ) Interim Management Statement January 1-June 30, 2022
Message from the CEO Our IBP-9414 clinical phase III development program is progressing well. We...
August 25, 2022
Infant Bacterial Therapeutics AB appoints Maria Ekdahl as CFO
Press Release June 30, 2022 Infant Bacterial Therapeutics AB (publ) announced today that Maria...
June 30, 2022
Annual General Meeting of Infant Bacterial Therapeutics
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2022, among...
May 4, 2022
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 31, 2022
Message from the CEO IBT's vision is to become an internationally leading company in the...
May 4, 2022
Notice to attend the Annual General Meeting of Infant Bacterial Therapeutics
Shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to the Annual General...
April 5, 2022
Infant Bacterial Therapeutics publishes Annual Report for 2021
Press release March 31, 2022 Infant Bacterial Therapeutics AB (publ) publishes today the Annual...
March 31, 2022
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2021
Press release February 4, 2022 Message from the CEO IBT’s ongoing pivotal phase lll clinical...
February 4, 2022
The Connection Study continues after pre-scheduled Data Monitoring Committee (DMC) review
On September 30, 2021 Infant Bacterial Therapeutics (IBT) announced that the company had reached a...
January 19, 2022
Infant Bacterial Therapeutics today announces that new patent protection is granted in Australia
Infant Bacterial Therapeutics AB (IBT) today announces that the Australian Patent Office has...
January 10, 2022
Infant Bacterial Therapeutics today announces new patent protection approvals in Brazil and in Hong Kong
Infant Bacterial Therapeutics AB today announces that the Patent Offices of Brazil and Hong Kong...
December 27, 2021
Infant Bacterial Therapeutics CFO leaves the company
Infant Bacterial Therapeutics ABs CFO Marie Louise Alamaa left the company to pursue new...
December 10, 2021
A Blinded Evaluation of the Connection Study – Sustained Feeding Tolerance (SFT) Correlates to Clinical Outcomes
A blinded evaluation of IBT’s Connection Study will be presented by Professor Josef Neu,...
December 6, 2021
Infant Bacterial Therapeutics AB (publ), Interim report January 1-September 30, 2021
Infant Bacterial Therapeutics AB (publ), Interim report January 1-September 30, 2021 Message...
October 29, 2021
Nomination Committee appointed for the 2022 Annual General Meeting (AGM) in Infant Bacterial Therapeutics (IBT).
Stockholm, October 29, 2021. The Chairman of IBT has established a Nomination Committee for the...
October 29, 2021
Next recruitment milestone reached in IBT’s Phase III Study.
Infant Bacterial Therapeutics (IBT) announces that the company has reached the next important...
September 30, 2021
After safety review The Connection study is now again open to recruit the smallest infants.
After safety review The Connection study is now again open to recruit the smallest infants....
September 22, 2021